基于美国FAERS数据库的药物引起唾液腺结石不良事件信号分析

doi:10.19803/j.1672-8629.20240508

中国药物警戒 ›› 2025, Vol. 22 ›› Issue (7): 799-804.
DOI: 10.19803/j.1672-8629.20240508

基于美国FAERS数据库的药物引起唾液腺结石不良事件信号分析

曹凯¹, 钱佩佩¹, 高鑫², 杨付田², 赵亮¹, 徐炳欣^3,4, 张现军^2,4,*

¹河南科技大学附属许昌市中心医院药学部,河南许昌 461000;
²河南科技大学附属许昌市中心医院口腔科,河南许昌 461000;
³河南科技大学附属许昌市中心医院临床医学研究中心,河南许昌 461000;
⁴河南省卫生健康委员会精准医学重点实验室,河南许昌 461000

收稿日期:2024-07-26 出版日期:2025-07-15 发布日期:2025-07-17
通讯作者: ^*通信作者：张现军,男,本科,主任医师,口腔医学与医疗管理。E-mail: 281074699@qq.com
作者简介:曹凯,男,硕士,副主任药师,临床药学与医院药学。
基金资助:
许昌市重点研发与推广专项（20230213065）

Mining of Risk Signals Adverse Events Related to Drug-Induced Salivary Gland Calculus Based on FAERS Database

CAO Kai¹, QIAN Peipei¹, GAO Xin², YANG Futian², ZHAO Liang¹, XU Bingxin^3,4, ZHANG Xianjun^2,4,*

¹Pharmacy Department, Xuchang Central Hospital Affiliated to Henan University of Science and Technology, Xuchang Henan 461000, China;
²Stomatology Department, Xuchang Central Hospital Affiliated to Henan University of Science and Technology, Xuchang Henan 461000, China;
³Clinical Research Center, Xuchang Central Hospital Affiliated to Henan University of Science and Technology, Xuchang Henan 461000, China;
⁴Henan Provincial Health Commission Key Laboratory of Precision Medicine, Xuchang Henan 461000, China

Received:2024-07-26 Online:2025-07-15 Published:2025-07-17

摘要/Abstract

摘要： 目的对药物引起的唾液腺结石进行不相称测定分析,为药物相关性唾液腺结石的预防提供参考。方法采用报告比值比（ROR）法和综合标准（MHRA）法对美国食品药品监督管理局不良事件报告系统（FAERS）中2012年4季度至2023年2季度的个例安全性报告数据中唾液腺结石有关不良反应信号进行检测。结果共检索到唾液腺结石相关报告211例,涉及主要怀疑或次要怀疑药物135个。经ROR法和MHRA法检测后,共有14种药物出现不相称测定信号（SDR）,分别为钙剂、马昔腾坦、美托洛尔、左甲状腺素、阿达木单抗、戈利木单抗、托珠单抗、唑来膦酸、地诺单抗、托吡酯、奥氮平、喹硫平、羟丁酸钠和美克洛嗪（按ATC编码排序）。结论检测到唾液腺结石相关SDR的药物14个。临床医务人员在应用上述药物时,应认识到唾液腺结石发生的潜在风险,积极监测并采取相应预防措施。

关键词: 唾液腺结石, 药品不良反应, 自发报告系统, 美国食品药品监督管理局不良事件报告系统, 不相称测定分析

Abstract: Objective To conduct a disproportionality analysis of drug-induced salivary gland calculus by using the individual case safety reports in the FDA Adverse Event Reporting System (FAERS) in order to provide a reference for prevention of this disease. Methods Data on individual case safety reports collected between the fourth quarter of 2012 and the second quarter of 2023 in the FAERS was retrieved. The reporting odds ratio (ROR) method and Medicines and Healthcare Products Regulatory Agency (MHRA) method were used for detection of signals of adverse drug reactions related to salivary gland calculus. Results A total of 211 reports related to salivary gland calculus were retrieved, involving 135 primary suspected or secondary suspected drugs. Using the ROR method and MHRA method, signals of disproportionate reporting (SDR) were detected in 14 drugs, which were calcium, macitentan, metoprolol, levothyroxine, adalimumab, golimumab, tocilizumab, zoledronic acid, denosumab, topiramate, olanzapine, quetiapine, sodium oxybate and meclizine (sorted by the ATC code). Conclusion There are 14 types of drugs with SDR related to salivary gland calculus detected in this study. Clinicians should be aware of the potential risks of salivary gland calculus when prescribing drugs mentioned above. Active monitoring and appropriate precautions are required.

Key words: Salivary Gland Calculus, Adverse Drug Reaction, Spontaneous Reporting System, FDA Adverse Event Reporting System, Disproportionality Analysis

中图分类号:

R969.3

曹凯, 钱佩佩, 高鑫, 杨付田, 赵亮, 徐炳欣, 张现军. 基于美国FAERS数据库的药物引起唾液腺结石不良事件信号分析[J]. 中国药物警戒, 2025, 22(7): 799-804.

CAO Kai, QIAN Peipei, GAO Xin, YANG Futian, ZHAO Liang, XU Bingxin, ZHANG Xianjun. Mining of Risk Signals Adverse Events Related to Drug-Induced Salivary Gland Calculus Based on FAERS Database[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 799-804.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240508

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I7/799

参考文献

[1] KRAAIJ S, KARAGOZOGLU KH, KENTER YA, et al.Systemic Diseases and the Risk of Developing Salivary Stones: a Case Control Study[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2015, 119(5): 539-543.
[2] MORTAZAVI H, TIZNO A, AZADI A, et al.What Is the Impact of Previous Cholelithiasis on Sialolithiasis: a Systematic Review and Meta-Analysis[J]. Saudi Dent J, 2024, 36(1): 44-51.
[3] GAMALELDIN O, MAGDY EA, ZOHEIR H, et al.The Role of Magnetic Resonance Imaging and Magnetic Resonance Sialography in the Evaluation of Salivary Sialolithiasis: Radiologic-Endoscopic Correlation[J]. Pol J Radiol, 2022, 87: e430-e437.
[4] JONAS E, MUCHNIK D, RABINOVICH I, et al.Characteristics of Sialolithiasis in Israel, a Big-Data Retrospective Study of 5100 Cases[J]. Oral Dis, 2025, 31(2): 503-509.
[5] HUOH KC, EISELE DW.Etiologic Factors in Sialolithiasis[J]. Otolaryngol Head Neck Surg, 2011, 145(6): 935-939.
[6] GUO ZJ, GUO XJ, XU JF, et al.Analysis for Adverse Events of Apalu-tamide Based on FAERS Database[J]. Chin J Pharmacoepidemiol(药物流行病学杂志), 2021, 30(11): 744-749.
[7] HATAHIRA H, ABE J, HANE Y, et al.Drug-Induced Gingival Hyperplasia: a Retrospective Study Using Spontaneous Reporting System Databases[J]. J Pharm Health Care Sci, 2017, 3: 19.
[8] LI ZY, JING YX, LI CX, et al.Research and Experience Reference of Foreign Typical Pharmacovigilance Database[J]. Chinese Journal of Drug Evaluation(中国药物评价) , 2021, 38(4): 265-273.
[9] JIANG M, WU Y, SHAH A, et al.Extracting and Standardizing Medication Information in Clinical Text-the Medex-UIMA System[J]. AMIA Jt Summits Transl Sci Proc, 2014, 2014: 37-42.
[10] FDA. What Is a Serious Adverse Event[EB/OL]. (2023-05-18)[2025-05-09]. https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event.
[11] YE XF.Progress and Thinking of Signal Detection Methodology on Post-Marketing Adverse Drug Reaction Surveillance[J]. Academic Journal of Naval Medical University(海军军医大学学报), 2022, 43(2): 117-122.
[12] FUSAROLI M, SALVO F, BEGAUD B, et al.The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement[J]. Drug Saf, 2024, 47(6): 575-584.
[13] ZHU ZP, LYU Q, YE XF, et al.Disproportionality of Adverse Events to KRAS G12C Inhibitors Based on the FAERS Database[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2025, 22(3): 297-304.
[14] ASHINDOITIANG JA, NWAGBARA VIC, UGBEM T, et al.Huge Sialolith of the Submandibular Gland: a Case Report and Review of Literature[J]. J Int Med Res, 2023, 51(1): 3000605221148443.
[15] YIU AJ, CALLAGHAN D, SULTANA R, et al.Vascular Calcification and Stone Disease: a New Look towards the Mechanism[J]. J Cardiovasc Dev Dis, 2015, 2(3): 141-164.
[16] SU YX, ZHANG K, KE ZF, et al.Increased Calcium and Decreased Magnesium and Citrate Concentrations of Submandibular/Sublingual Saliva in Sialolithiasis[J]. Arch Oral Biol, 2010, 55(1): 15-20.
[17] JUNG SY, CHANG SA, SONG JM, et al.Real-World Safety and Clinical Outcomes of Macitentan in Asian Patients with Pulmonary Arterial Hypertension: a Prospective Multicenter Study[J]. Drugs Real World Outcomes, 2023, 10(1): 41-49.
[18] VENTIMIGLIA MS, RODRIGUEZ MR, MORALES VP, et al.Endothelins Participate in the Central and Peripheral Regulation of Submandibular Gland Secretion in the Rat[J]. Am J Physiol Regul Integr Comp Physiol, 2011, 300(1): R109-R120.
[19] SCULLY C.Drug Effects on Salivary Glands: Dry Mouth[J]. Oral Dis, 2003, 9(4): 165-176.
[20] NEDERFORS T.Xerostomia: Prevalence and Pharmacotherapy with Special Reference to Beta-Adrenoceptor Antagonists[J]. Swed Dent J Suppl, 1996, 116: 1-70.
[21] NEDERFORS T, DAHLÖF C. Effects on Salivary Flow Rate and Composition of Withdrawal of and Re-Exposure to the Beta 1-Selective Antagonist Metoprolol in a Hypertensive Patient Population[J]. Eur J Oral Sci, 1996, 104(3): 262-268.
[22] NAIK MM, VASSANDACOUMARA V.Qualitative and Quantitative Salivary Changes and Subjective Oral Dryness among Patients with Thyroid Dysfunction[J]. Indian J Dent Res, 2018, 29(1): 16-21.
[23] XIAO YD, YANG HM, DAN HX.Adverse Reactions of Targeted Anticancer Agents in Oral Cavity: Manifestation and Management[J]. International Journal of Stomatology(国际口腔医学杂志) , 2018, 45(2): 140-144.
[24] BAKHTIARI S, SEHATPOUR M, MORTAZAVI H, et al.Orofacial Manifestations of Adverse Drug Reactions: a Review Study[J]. Clujul Med, 2018, 91(1): 27-36.
[25] ALSAKRAN ALTAMIMI M.Update Knowledge of Dry Mouth-a Guideline for Dentists[J]. Afr Health Sci, 2014, 14(3): 736-742.
[26] KREHER D, ERNST BLV, ZIEBOLZ D, et al.Dental Caries in Adult Patients with Rheumatoid Arthritis-a Systematic Review[J]. J Clin Med, 2023, 12(12): 4128.
[27] CHEN H, HE Y.Interpretation of Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline[J]. Chinese Journal of Stomatology(中华口腔医学杂志) , 2022, 57(2): 128-135.
[28] SURYANI IR, AHMADZAI I, THAT MT, et al.Are Medication-Induced Salivary Changes the Culprit of Osteonecrosis of the Jaw? a Systematic Review[J]. Front Med (Lausanne), 2023, 10: 1164051.
[29] BUHLER AV, HUYNH P, LOW P, et al.Possible Drug-Associated Sialolithiasis from the Bicarbonate Anhydrase Inhibitor Topiramate: a Case Report and Literature Review[J]. J Oral Maxillofac Surg, 2016, 74(12): 2447-2452.
[30] PARKKILA S, PARKKILA AK, JUVONEN T, et al.Distribution of the Carbonic Anhydrase Isoenzymes I,Ⅱ, and VI in the Human Alimentary Tract[J]. Gut, 1994, 35(5): 646-650.
[31] SEKINE Y, RIKIHISA T, OGATA H, et al.Correlations between in vitro Affinity of Antipsychotics to Various Central Neurotransmitter Receptors and Clinical Incidence of Their Adverse Drug Reactions[J]. Eur J Clin Pharmacol, 1999, 55(8): 583-587.
[32] DAUVILLIERS Y, BOGAN RK, ŠONKA K, et al.Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: a Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy[J]. Nat Sci Sleep, 2022, 14: 531-546.
[33] THORPY MJ, ARNULF I, FOLDVARY-SCHAEFER N, et al.Efficacy and Safety of Lower-Sodium Oxybate in an Open-Label Titration Period of a Phase 3 Clinical Study in Adults with Idiopathic Hypersomnia[J]. Nat Sci Sleep, 2022, 14: 1901-1917.
[34] WANG J, ZOU D, LI Y, et al.Drug-Induced Tooth Discoloration: an Analysis of the US Food and Drug Administration Adverse Event Reporting System[J]. Front Pharmacol, 2023, 14: 1161728.

基于美国FAERS数据库的药物引起唾液腺结石不良事件信号分析

Mining of Risk Signals Adverse Events Related to Drug-Induced Salivary Gland Calculus Based on FAERS Database

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	王春婷, 陈亚飞, 李婷婷. 化学药品上市后说明书安全信息修订考虑要点[J]. 中国药物警戒, 2025, 22(7): 776-779.
[2]	朱会卷, 任经天. 狂犬病人免疫球蛋白安全性风险分析[J]. 中国药物警戒, 2025, 22(7): 786-789.
[3]	陈耀哲, 詹云丽, 宋兴栋, 朱漫玉, 欧雪媚, 李楚云. 48例哌拉西林钠他唑巴坦钠血液系统不良反应分析[J]. 中国药物警戒, 2025, 22(7): 794-798.
[4]	林璐, 赵安职, 陈锦辉, 李忠文, 黄国华, 钟诗龙. 注射用头孢噻肟钠舒巴坦钠致迟发型超敏反应1例分析[J]. 中国药物警戒, 2025, 22(7): 809-811.
[5]	唐炯, 曾语琦. 舒格利单抗注射液致动眼神经麻痹1例分析[J]. 中国药物警戒, 2025, 22(7): 812-814.
[6]	王媛, 李若柠, 郭展立, 张磊, 李嘉媛, 冬颖, 孙建军. 替罗非班注射液致极重度血小板减少症1例分析[J]. 中国药物警戒, 2025, 22(7): 815-818.
[7]	雷建林, 王娜, 王文筝, 王岩. 复方妥英麻黄茶碱片致苯妥英钠中毒1例分析[J]. 中国药物警戒, 2025, 22(7): 819-822.
[8]	李敏, 李春磊, 孙翠翠, 于文雯, 孙青, 戚迎梅, 刘安昌. 阿布昔替尼片致急性泛发性发疹性脓疱病1例分析[J]. 中国药物警戒, 2025, 22(7): 823-825.
[9]	钟心茹, 杨德盈, 官堂明, 陈驹, 江东波. 奥妥珠单抗治疗滤泡性淋巴瘤相关不良反应的研究进展[J]. 中国药物警戒, 2025, 22(7): 831-835.
[10]	赵玉芳, 世伟, 杨胜男, 刘治恩, 雷雯朴, 张亚男, 赵科, 郭浩. 983例奥沙利铂不良反应报告分析[J]. 中国药物警戒, 2025, 22(6): 645-648.
[11]	郑斯莉, 张晓庆. 133例女性患者药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(6): 654-658.
[12]	傅蔚然, 邹东梅, 倪婧, 孙婉玲, 郭轶先. 塞替派预处理方案联合自体造血干细胞移植治疗原发中枢神经系统[J]. 中国药物警戒, 2025, 22(6): 664-668.
[13]	景天舒, 路国涛, 王胜锋. 基于美国FAERS数据库的替尔泊肽胰腺相关不良事件信号分析[J]. 中国药物警戒, 2025, 22(6): 669-673.
[14]	王浩, 马劲夫, 马瑞, 李晓刚, 赵强, 张弦. 注射用头孢哌酮舒巴坦钠致血小板减少1例分析[J]. 中国药物警戒, 2025, 22(6): 686-688.
[15]	孙钟慧, 刘英纯, 董琪, 张倩, 杨静. 硫酸羟氯喹片致药物超敏反应综合征1例分析[J]. 中国药物警戒, 2025, 22(6): 689-692.